Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STC's cryosurgical system's expanded uses:

This article was originally published in Clinica

Executive Summary

STC Technologies has received 510(k) clearance from the US FDA to market its Histofreezer portable cryosurgical system for treating actinic keratosis and lentigo (liver spots). Acitinic keratosis is often a precursor to skin cancer and if treated early, remains harmless, according to the Lehigh Valley, Pennsylvania-based company. The device consists of a canister of cryogen which is applied to the lesions through an attached foam bud and is also used for the treatment of other skin abnormalities such as common warts and genital lesions.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel